<DOC>
	<DOC>NCT02822157</DOC>
	<brief_summary>This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.</brief_summary>
	<brief_title>Circulating Tumor DNA Guiding (Olaparib) LynparzaÂ® Treatment in Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>with recurrent epithelial carcinoma of the ovary, fallopian tube or primary peritoneum At least 1 previous line of chemotherapy Measurable disease Patients have a normal organ and bone marrow function measured within 28 days of randomization WHO 02 Primary platinumrefractory disease Known hypersensitivity to olaparib Resting ECG with QTc &gt; 470 msec Concomitant use of known potent CYP3A4 inhibitors Symptomatic uncontrolled brain metastases Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>